Cargando…

Management of clinical relevant drug-drug interactions with antipsychotics in nursing homes

INTRODUCTION: Antipsychotics (APs) have been linked to several clinically relevant drug-drug interactions (leading, e.g. to QT-prolongation, torsades de pointes) but little is known about their management in nursing homes residents. Our aim was to characterise clinically relevant drug-drug interacti...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernardo, Catarina, Aguiar, João Pedro, da Costa, Filipa Alves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480561/
http://dx.doi.org/10.1080/07853890.2021.1896843
_version_ 1784576478529191936
author Bernardo, Catarina
Aguiar, João Pedro
da Costa, Filipa Alves
author_facet Bernardo, Catarina
Aguiar, João Pedro
da Costa, Filipa Alves
author_sort Bernardo, Catarina
collection PubMed
description INTRODUCTION: Antipsychotics (APs) have been linked to several clinically relevant drug-drug interactions (leading, e.g. to QT-prolongation, torsades de pointes) but little is known about their management in nursing homes residents. Our aim was to characterise clinically relevant drug-drug interactions involving APs and to assess their prevalence in nursing homes residents. MATERIALS AND METHODS: We conducted a cross-sectional study in two nursing homes in Portugal. Patients were included if they were older ≥65 and prescribed at least one AP (registered in medical charts). Interactions were identified using Drug Interaction Chequer (Medscape [1]) and supplemented with the summary of product characteristics (SmPC) when deemed necessary. Clinical relevant interactions were defined as serious or contraindicated interactions according to Medscape tool. Data were analysed using univariate statistics (Microsoft Excel 2016). RESULTS: A total of 59 patients (83.7 ± 7.1 years) were analysed, 79.7% (n = 47) females. A mean of 1.6 ± 0.7 antipsychotics were prescribed/patient, mostly on a regular basis (61.0%; n = 36). The majority were exclusively prescribed atypical APs (59.3%; n = 35), 28.8% (n = 17) simultaneously atypical and typical APs and 11.9% (n = 7) prescribed only typical APs. Nearly 90% (n = 52; 88.1%) of patients reported interactions with APs, (mean = 2.9 ± 2.3/patient). A total of 169 interactions with APs were found, mainly with antidepressants (27.2%; n = 46), benzodiazepines (22.4%; n = 38), and other antipsychotics (10.6%; n = 18). The majority of AP-drug interactions (83.4%; n = 141) were classified as “to be closely monitored”, mostly due to the sedation effect (56.7%; n = 80). Quetiapine was the AP most often involved in interactions (45.6%; n = 77), where 9.1% (n = 7) were considered “serious”. Haloperidol also registered 37 interactions (21.9%), four of which resulted in increased QTc interval (10.8%). DISCUSSION AND CONCLUSIONS: Data showed that one third of patients had clinically relevant AP-drug interactions. Future work will include the development of a user-friendly booklet on clinical relevant drug-drug interactions in elderly patients using APs, expected to contribute to enhanced patient safety and a more rational use of medicines.
format Online
Article
Text
id pubmed-8480561
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-84805612022-03-03 Management of clinical relevant drug-drug interactions with antipsychotics in nursing homes Bernardo, Catarina Aguiar, João Pedro da Costa, Filipa Alves Ann Med Abstract 25 INTRODUCTION: Antipsychotics (APs) have been linked to several clinically relevant drug-drug interactions (leading, e.g. to QT-prolongation, torsades de pointes) but little is known about their management in nursing homes residents. Our aim was to characterise clinically relevant drug-drug interactions involving APs and to assess their prevalence in nursing homes residents. MATERIALS AND METHODS: We conducted a cross-sectional study in two nursing homes in Portugal. Patients were included if they were older ≥65 and prescribed at least one AP (registered in medical charts). Interactions were identified using Drug Interaction Chequer (Medscape [1]) and supplemented with the summary of product characteristics (SmPC) when deemed necessary. Clinical relevant interactions were defined as serious or contraindicated interactions according to Medscape tool. Data were analysed using univariate statistics (Microsoft Excel 2016). RESULTS: A total of 59 patients (83.7 ± 7.1 years) were analysed, 79.7% (n = 47) females. A mean of 1.6 ± 0.7 antipsychotics were prescribed/patient, mostly on a regular basis (61.0%; n = 36). The majority were exclusively prescribed atypical APs (59.3%; n = 35), 28.8% (n = 17) simultaneously atypical and typical APs and 11.9% (n = 7) prescribed only typical APs. Nearly 90% (n = 52; 88.1%) of patients reported interactions with APs, (mean = 2.9 ± 2.3/patient). A total of 169 interactions with APs were found, mainly with antidepressants (27.2%; n = 46), benzodiazepines (22.4%; n = 38), and other antipsychotics (10.6%; n = 18). The majority of AP-drug interactions (83.4%; n = 141) were classified as “to be closely monitored”, mostly due to the sedation effect (56.7%; n = 80). Quetiapine was the AP most often involved in interactions (45.6%; n = 77), where 9.1% (n = 7) were considered “serious”. Haloperidol also registered 37 interactions (21.9%), four of which resulted in increased QTc interval (10.8%). DISCUSSION AND CONCLUSIONS: Data showed that one third of patients had clinically relevant AP-drug interactions. Future work will include the development of a user-friendly booklet on clinical relevant drug-drug interactions in elderly patients using APs, expected to contribute to enhanced patient safety and a more rational use of medicines. Taylor & Francis 2021-09-28 /pmc/articles/PMC8480561/ http://dx.doi.org/10.1080/07853890.2021.1896843 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract 25
Bernardo, Catarina
Aguiar, João Pedro
da Costa, Filipa Alves
Management of clinical relevant drug-drug interactions with antipsychotics in nursing homes
title Management of clinical relevant drug-drug interactions with antipsychotics in nursing homes
title_full Management of clinical relevant drug-drug interactions with antipsychotics in nursing homes
title_fullStr Management of clinical relevant drug-drug interactions with antipsychotics in nursing homes
title_full_unstemmed Management of clinical relevant drug-drug interactions with antipsychotics in nursing homes
title_short Management of clinical relevant drug-drug interactions with antipsychotics in nursing homes
title_sort management of clinical relevant drug-drug interactions with antipsychotics in nursing homes
topic Abstract 25
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480561/
http://dx.doi.org/10.1080/07853890.2021.1896843
work_keys_str_mv AT bernardocatarina managementofclinicalrelevantdrugdruginteractionswithantipsychoticsinnursinghomes
AT aguiarjoaopedro managementofclinicalrelevantdrugdruginteractionswithantipsychoticsinnursinghomes
AT dacostafilipaalves managementofclinicalrelevantdrugdruginteractionswithantipsychoticsinnursinghomes